Lutikizumab is a humanized dual-variable domain (DVD) immunoglobulin G1 kappa (IgG1κ) that targets the inflammatory cytokines human interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β), exhibiting anti-inflammatory properties. It shows potential for treating knee osteoarthritis in patients with synovitis. MW: 196.82 KD.